CN115043821B - 作为alk抑制剂的氨基嘧啶 - Google Patents

作为alk抑制剂的氨基嘧啶 Download PDF

Info

Publication number
CN115043821B
CN115043821B CN202210533398.XA CN202210533398A CN115043821B CN 115043821 B CN115043821 B CN 115043821B CN 202210533398 A CN202210533398 A CN 202210533398A CN 115043821 B CN115043821 B CN 115043821B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
cancer
compound according
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210533398.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN115043821A (zh
Inventor
王少萌
陈建勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan Ann Arbor filed Critical University of Michigan Ann Arbor
Priority to CN202210533398.XA priority Critical patent/CN115043821B/zh
Publication of CN115043821A publication Critical patent/CN115043821A/zh
Application granted granted Critical
Publication of CN115043821B publication Critical patent/CN115043821B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202210533398.XA 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶 Active CN115043821B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210533398.XA CN115043821B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662380818P 2016-08-29 2016-08-29
US62/380,818 2016-08-29
PCT/US2017/048845 WO2018044767A2 (en) 2016-08-29 2017-08-28 Aminopyrimidines as alk inhibitors
CN201780057518.0A CN109715620B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶
CN202210533398.XA CN115043821B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780057518.0A Division CN109715620B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶

Publications (2)

Publication Number Publication Date
CN115043821A CN115043821A (zh) 2022-09-13
CN115043821B true CN115043821B (zh) 2024-08-06

Family

ID=59846649

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210533398.XA Active CN115043821B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶
CN201780057518.0A Active CN109715620B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780057518.0A Active CN109715620B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶

Country Status (11)

Country Link
US (2) US10709705B2 (enExample)
EP (2) EP4001273A3 (enExample)
JP (2) JP7094566B2 (enExample)
KR (1) KR102530871B1 (enExample)
CN (2) CN115043821B (enExample)
AU (2) AU2017319135B2 (enExample)
IL (1) IL264638B (enExample)
MX (2) MX389265B (enExample)
NZ (1) NZ751713A (enExample)
SG (2) SG11201901251SA (enExample)
WO (1) WO2018044767A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019314625B2 (en) * 2018-07-31 2022-05-12 Ascentage Pharma (Suzhou) Co., Ltd. Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor
CN111171033B (zh) * 2018-11-09 2021-11-02 天津大学 一种嘧啶衍生物及其合成方法和应用
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法
TWI769470B (zh) * 2019-06-25 2022-07-01 大陸商蘇州亞盛藥業有限公司 用於治療疾病的fak抑制劑和btk抑制劑的組合
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230381176A1 (en) * 2020-09-25 2023-11-30 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer
CN115212311B (zh) * 2021-04-19 2024-08-09 苏州亚盛药业有限公司 一种药物组合及其用途
CA3238857A1 (en) * 2021-12-09 2023-06-15 Oncobix Co., Ltd. Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
CN116332919B (zh) * 2022-03-30 2025-08-26 苏州亚盛药业有限公司 一种alk抑制剂化合物及其中间体的制备方法
CN120513241A (zh) * 2023-01-20 2025-08-19 苏州亚盛药业有限公司 Alk抑制剂或其盐、溶剂合物的结晶形式及其制备方法和应用
KR20250160958A (ko) * 2023-03-22 2025-11-14 어센테지 파마 (쑤저우) 컴퍼니 리미티드 약학적 조합 및 이의 응용
WO2025232723A1 (en) * 2024-05-06 2025-11-13 Ascentage Pharma (Suzhou) Co., Ltd. Treatment method with focal adhesion kinase inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081813A1 (zh) * 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015130014A1 (ko) * 2014-02-28 2015-09-03 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PT1660458E (pt) 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
US20070105839A1 (en) * 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
DK2253614T3 (da) * 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
NZ577197A (en) 2006-12-08 2011-02-25 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
MX2010010968A (es) 2008-04-07 2010-10-26 Irm Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2012051587A1 (en) 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in egfr-driven cancers
RS54189B1 (sr) * 2011-02-02 2015-12-31 Novartis Ag Postupci za korišćenje inibitora alk

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081813A1 (zh) * 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015130014A1 (ko) * 2014-02-28 2015-09-03 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Also Published As

Publication number Publication date
CN109715620B (zh) 2022-05-06
JP2019528307A (ja) 2019-10-10
US20200330464A1 (en) 2020-10-22
MX389265B (es) 2025-03-20
SG11201901251SA (en) 2019-03-28
WO2018044767A3 (en) 2018-04-12
JP7094566B2 (ja) 2022-07-04
US10709705B2 (en) 2020-07-14
MX2019002393A (es) 2019-07-08
EP3504203B1 (en) 2022-09-28
AU2017319135A1 (en) 2019-04-04
US11110090B2 (en) 2021-09-07
BR112019003897A2 (pt) 2019-05-21
EP4001273A3 (en) 2022-08-24
CN115043821A (zh) 2022-09-13
JP2022120151A (ja) 2022-08-17
WO2018044767A2 (en) 2018-03-08
AU2021203098A1 (en) 2021-06-10
US20190175595A1 (en) 2019-06-13
NZ751713A (en) 2022-07-01
CA3033223A1 (en) 2018-03-08
AU2017319135B2 (en) 2021-03-18
EP3504203A2 (en) 2019-07-03
KR102530871B1 (ko) 2023-05-09
IL264638B (en) 2021-08-31
KR20190039760A (ko) 2019-04-15
AU2021203098B2 (en) 2023-05-25
EP4001273A2 (en) 2022-05-25
MX2022000376A (es) 2022-02-10
SG10201914030UA (en) 2020-03-30
CN109715620A (zh) 2019-05-03

Similar Documents

Publication Publication Date Title
CN115043821B (zh) 作为alk抑制剂的氨基嘧啶
JP2019511528A (ja) Ｂｅｔタンパク質分解剤
US20210087188A1 (en) 5,6-dihydro-1 1h-indolo{2,3-b}quinolin- 11-one compounds as alk inhibitors
CN112119080B (zh) 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物
CN110636843A (zh) 作为共价多发性内分泌腺瘤蛋白抑制剂的哌啶
CN111936465A (zh) 作为共价menin抑制剂的哌啶化合物
AU2017363161B2 (en) 5,6-dihydro-11H-indolo[2,3-b]quinolin-11-ones as ALK inhibitors
HK40077976A (en) Aminopyrimidines as alk inhibitors
CA3033223C (en) Aminopyrimidines as alk inhibitors
HK40077976B (zh) 作为alk抑制剂的氨基嘧啶
HK40007649A (en) Aminopyrimidines as alk inhibitors
HK40007649B (en) Aminopyrimidines as alk inhibitors
HK40041770B (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40041770A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40012150A (en) 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-one compounds as alk inhibitors
HK40013399A (en) 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-ones as alk inhibitors
BR112019003897B1 (pt) Compostos de aminopirimidinas como inibidores de alk, composição farmacêutica bem como seus usos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077976

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant